Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its ...

Pneumococcal infections can be very serious – they include pneumonia, meningitis, and bacteremia (a blood infection), as well ...

Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.

SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due to the ongoing patent dispute with Pfizer, the company has been ...

The introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) in the U.S. in 2000 was a welcome addition to our preventive armamentarium; however, questions remain regarding the degree ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 – has started pivotal trials in the prevention of both paediatric Streptococcus pneumoniae, which remains a major public health ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

South Korean vaccine company SK Bioscience said it has prevailed in a lawsuit brought by Pfizer that accused it of infringing on the patent for the drugmaker's Prevnar 13 vaccine.

South Korean vaccine maker SK Bioscience has secured a final court victory over US pharma major Pfizer in a long-running ...

SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due ...